title: Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis.
abstract: OBJECTIVE
  We sought to estimate the cost-effectiveness of magnesium neuroprophylaxis for all women at risk for preterm birth <32 weeks.
  
  
  METHODS
  A decision analytic and cost-effectiveness model was designed to compare use of magnesium for neuroprophylaxis vs no treatment for women at risk for preterm birth <32 weeks due to preterm premature rupture of membranes or preterm labor from 24-32 weeks. Outcomes included neonatal death and moderate-severe cerebral palsy. Effectiveness was reported in quality-adjusted life years.
  
  
  RESULTS
  Magnesium for neuroprophylaxis led to lower costs ($1739 vs $1917) and better outcomes (56.684 vs 56.678 quality-adjusted life years). However, sensitivity analysis revealed the model to be sensitive to estimates of effect of magnesium on risk of moderate or severe cerebral palsy as well as neonatal death.
  
  
  CONCLUSIONS
  Based on currently published evidence for efficacy, magnesium for neuroprophylaxis in women at risk to deliver preterm is cost-effective.
authors: Department of Obstetrics and Gynecology at Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
authors: Alison G
authors: AG
authors: Cahill
authors: Anthony O
authors: AO
authors: Odibo
authors: Molly J
authors: MJ
authors: Stout
authors: William A
authors: WA
authors: Grobman
authors: George A
authors: GA
authors: Macones
authors: Aaron B
authors: AB
authors: Caughey
mesh_terms: D000927:Anticonvulsants / Q000191:economics / Q000627:therapeutic use; D002547:Cerebral Palsy / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis / Q000191:economics / Q000706:statistics & numerical data; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000191:economics / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008278:Magnesium Sulfate / Q000191:economics* / Q000627:therapeutic use*; D011247:Pregnancy; D011295:Prenatal Care / Q000191:economics / Q000706:statistics & numerical data; D019057:Quality-Adjusted Life Years; D012307:Risk Factors
chemical_list: D000927:Anticonvulsants; D008278:Magnesium Sulfate